Medicine given after exposure to prevent leprosy
Part of Infections clinical trials.
This Phase 3 study tests whether taking preventive antibiotics after possible contact can stop leprosy from developing. If it works, it could protect people in affected communities from getting leprosy (and possibly related infections).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You live in the study area clusters on Anjouan or Mohéli
- You are age 2 or older (and not under 20 kg if you would need bedaquiline)
- You can agree to leprosy and tuberculosis screening and the prevention medicine if you qualify
- You should not have signs of current (active) leprosy
- You must not have signs of active tuberculosis, in the lungs or elsewhere
- You have not taken rifampicin or bedaquiline in the past 2 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at new ways to diagnose and treat leprosy. It includes patients with a more serious form of leprosy and the people who live closely with them, to help stop the spread of the disease.
This study tests if bedaquiline can prevent tuberculosis (TB) in people who have been in close contact with someone with active TB, including people living with HIV. If you qualify, you would take the study medicine and be monitored to see if it prevents you from developing TB.
This trial tests a shorter treatment for tuberculosis (TB) using a combination of three medicines: bedaquiline, moxifloxacin, and pyrazinamide. If you have TB in your lungs, this could be a way to treat it more quickly than the standard longer course.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This Phase 3 trial tests an oral medicine (Sudapyridine/WX-081) to treat people with rifampicin-resistant pulmonary tuberculosis. It compares how well the study drug works when you stop prior tuberculosis medicines and go through a short “washout” period first.
This study tests a 6-month treatment with four oral medicines (bedaquiline, delamanid, linezolid, and levofloxacin) for people whose TB is resistant to rifampin. The goal is to see if this all-pill combination is safe and effective in treating this difficult type of TB.
Hear when a new Leprosy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.